Prana candidate reduces Abeta levels

By Dylan Bushell-Embling
Thursday, 10 July, 2008

Key findings from Prana Biotechnology's [ASX: PBT] preclinical research of its proprietary PBT2 Alzheimer's drug have been published in the prestigious scientific journal Neuron.

The article, "Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxyquinoline analogs is associated with decreased interstitial Abeta," can be viewed on-line by Neuron subscribers.

PBT2 was found to rapidly and profoundly improve cognition in transgenic mice, by substantially reducing the amount of Abeta - amyloid beta, the main constituent of Alzheimer's plaques - in the brain over a nine-month period.

The findings will be presented at the 11th International Conference on Alzheimer's Disease, to be held in Chicago at the end of the month.

Related News

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...

Maternal cannabis use puts kids at risk of behavioural problems

Children exposed to their mother's cannabis use during pregnancy and after birth are three...

Over-the-counter pain relievers may improve concussion recovery

People who take over-the-counter pain relievers after a concussion may recover faster than those...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd